Flag of the European Union EU Clinical Trials Register Help

Clinical trials for An Open-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,988 result(s) found for: An Open-. Displaying page 465 of 550.
    «« First « Previous 461  462  463  464  465  466  467  468  469  Next» Last»»
    EudraCT Number: 2021-002590-26 Sponsor Protocol Number: PTA17333 Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A French multicenter Phase 4 open label extension study of long term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France
    Medical condition: Glycogen storage disease type II
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003761-18 Sponsor Protocol Number: BHV3000-312 Start Date*: 2022-01-20
    Sponsor Name:Biohaven Pharmaceuticals Inc.
    Full Title: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < ...
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000672-11 Sponsor Protocol Number: GS-US-465-4439 Start Date*: 2022-03-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
    Medical condition: Chronic Hepatitis B (CHB)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001979-23 Sponsor Protocol Number: DANTE/FLOT8 Start Date*: 2018-06-06
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A randomized, open-label Phase II/III efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastri...
    Medical condition: locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005356-10 Sponsor Protocol Number: IB1001-301 Start Date*: 2022-03-15
    Sponsor Name:IntraBio Ltd
    Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study
    Medical condition: Niemann-Pick Disease type C (NPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001666-35 Sponsor Protocol Number: Kar-013 Start Date*: 2023-01-05
    Sponsor Name:Karuna Therapeutics, Inc.
    Full Title: An Open Label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000557-88 Sponsor Protocol Number: Anti-CD19-ALL Start Date*: 2022-11-14
    Sponsor Name:University Hospital Tuebingen
    Full Title: A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage L...
    Medical condition: B-lineage (CD19 positive) ALL (B, pro-B, pre-B or c-ALL) refractory to standard treatment or with relapsed disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024338 Leukemia lymphoblastic acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004938-38 Sponsor Protocol Number: ADVANCE2020 Start Date*: 2021-12-08
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: ADVANCE: A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
    Medical condition: Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008594 Cholangiocarcinoma non-resectable LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006487-24 Sponsor Protocol Number: ADNorGC Start Date*: Information not available in EudraCT
    Sponsor Name:Helse Bergen HF
    Full Title: A registry-based, open-label, randomized study to investigate quality-of-life with Plenadren compared with Cortison in participants aged 16-80 with newly diagnosed primary adrenal insufficiency
    Medical condition: Primary adrenal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10052381 Primary adrenal insufficiency PT
    Population Age: Adolescents, Under 18, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004446-29 Sponsor Protocol Number: LIBERAL-Trial Start Date*: 2017-10-30
    Sponsor Name:University Hospital Wuerzburg, Institution under public law, represented by the Medical Director
    Full Title: Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients
    Medical condition: Elderly patients (>= 70 years) undergoing intermediate- or high-risk non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    27.0 10022117 - Injury, poisoning and procedural complications 10048861 Anaemia postoperative PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002928-12 Sponsor Protocol Number: CT-P47_3.2 Start Date*: 2023-01-26
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Single-arm, Open-label, Multiple-dose, Phase 3 Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients with Moderate to Severe Active Rheumatoid Arthritis
    Medical condition: Moderate to severe active rheumatoid arthritis (RA) diagnosed according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006621-22 Sponsor Protocol Number: COVIC-19-G Start Date*: 2022-02-14
    Sponsor Name:DRK-Blutspendedienst Baden-Württemberg - Hessen gGmbH
    Full Title: A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new path...
    Medical condition: Clinically Vulnerable Individuals with Mild COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 10022891 - Investigations 10084355 COVID-19 virus test positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001702-88 Sponsor Protocol Number: 011-007 Start Date*: 2006-08-07
    Sponsor Name:Novacea, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
    Medical condition: For the treatment of metastatic androgen independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) HU (Prematurely Ended) CZ (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002239-31 Sponsor Protocol Number: VX20-445-112 Start Date*: 2022-03-18
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005722-28 Sponsor Protocol Number: 2020/3188 Start Date*: 2021-04-29
    Sponsor Name:Gustave Roussy
    Full Title: Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response t...
    Medical condition: Patients with human epidermal growth factor receptor 3-overexpressing (HER3-high) and hormone-receptor positive (HR+) advanced breast cancer who have already received standard therapy for HR+ advan...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003662-14 Sponsor Protocol Number: GN17CA082 Start Date*: 2019-05-13
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, rand...
    Medical condition: People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-004216-22 Sponsor Protocol Number: C602 Start Date*: 2019-09-25
    Sponsor Name:Soleno Therapeutics UK Ltd.
    Full Title: An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome
    Medical condition: Hyperphagia associated with Prader-Willi Syndrome (PWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020710 Hyperphagia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-003076-35 Sponsor Protocol Number: F3Z-VI-S019 Start Date*: 2006-09-26
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: Treatment Strategies in Patients with Type 2 Diabetes Mellitus Not Achieving Glycemic Control while on Therapy with Premixed Insulin Analogues and Metformin: A Comparison of Insulin Lispro MM Inte...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000832-13 Sponsor Protocol Number: 14/P/153 Start Date*: 2015-09-30
    Sponsor Name:University Hospitals Plymouth NHS Trust
    Full Title: Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma
    Medical condition: Untreated symptomatic Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 461  462  463  464  465  466  467  468  469  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:29:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA